Events Calendar


/Portals/0/NADevEventsImages/SEBC 29th May Image_800.png

OBN Digital: 'How to Accelerate Drug Treatments Through Better Decision-Making in Early Phase Clinical Trials'

Event Start Date: Friday, May 29, 2020 8:00 AM

Event End Date: Friday, May 29, 2020 8:00 PM

Event Locations
Digital Event

OBN DIGITAL

'How to Accelerate Drug Treatments Through Better Decision-Making in Early Phase Clinical Trials'

Friday 29 May | Available from 8:00 - 20:00 

Kindly Supported by Oxford BioEscalator

 

We are pleased to announce details of this Digital Event, which will be addressing the topic:  'How to Accelerate Drug Treatments Through Better Decision-Making in Early Phase Clinical Trials'. 

Outline: One of the most significant challenges facing global healthcare today remains how to translate novel therapies quickly and sustainably from laboratory to clinic.

The number of novel drug targets that are being identified is on the rise, whilst drug-development costs are increasing, timelines are getting longer, and success rates are falling.  Now is the time for a step-change in how new drugs are brought to market thus allowing patients earlier access to much-needed therapies.

But how can this be achieved?  The acceleration of drug treatments needs to be combined with improved quality and compliance, enhanced patient and healthcare-professional experience, better insights and decision making, and a reduction in development costs.

During this digital event, we will bring together three experts from Academia, R&D and a CRO, to share their insight and expertise on the issues facing drug development, where the solutions lie and the tangible improvements that are currently being made.


Event Host:
Dr Elodie Siney, 
Oxford BioEscalator 

Keynote Speakers:
Professor Duncan Richards, NDORMS   
Duncan has been recently appointment to the newly created Climax Professorship of Clinical Therapeutics, Duncan is working to establish a new Centre for Clinical Therapeutics based at the Botnar Research Centre and St Hilda’s, which will work with a diverse range of Oxford biomedical researchers and the pharmaceutical, biotechnology and diagnostics industries, to drive new drug treatments through decision-making in early phase clinical trials.

Helen Underwood, Thermo Fisher Scientific 
Helen holds the position of Director, Strategic Client Relationships, at Fisher Clinical Services. With over 20 years experience in the clinical trials environment, her capabilities include demand planning, sourcing, production, project & relationship management for both IMP and ancillary supplies.

Dr Richard Brown, PsiOxus Therapeutics
Richard holds the position of Project Director, at PsiOxus Therapeutics. Providing project leadership for the enadenotucriev oncolytic virus programme, and is accountable for timelines, quality and costs across the programme.

 

About OBN's Digital Events

The event will be pre-recorded, and available for viewing by registered delegates from 08:00 – 20:00 BST on Friday 29 May 2020.

A Q&A session will follow the keynote presentations, and we welcome audience questions in advance of the event. Please send your questions to events@obn.org.uk by Wednesday 20 May and our speakers will answer them during the Q&A session.

Virtual Partnering will be available for registered delegates between 10:00 – 12:00 BST on Friday 29 May. Registered delegates can take part in 15-minute 1:1 meetings, which can be requested and scheduled in the run up to the event.

 

About BioEscalator

The BioEscalator has been designed with early-stage businesses in mind: you can rent just one bench in our Innovation Lab or a small lab of your own. We also have shared core facilities. If you would like to discuss your particular needs, please get in touch.

The BioEscalator houses and supports companies where:

  • The company's work is based on early-stage, innovative, high quality science that has potential to make a significant positive impact on healthcare in its broadest sense.
  • There is an overlap between the company's work and the University's research.
  • The company has the potential for high growth.​

The BioEscalator has been funded by the government's City Deal (£11m), as part of a group of 4 innovation centres in Oxfordshire - with centres at the University's Begbroke Science Park, Harwell and Culham - and University investment.